Failed Back Surgery Treatment in Birmingham & Bessemer, AL

Failed Back Surgery Treatment at Alabama Pain Physicians

If you've had back surgery and still have pain — or your pain is worse — you're not alone. Failed back surgery syndrome (FBSS) affects up to 40% of spinal surgery patients. Our physicians specialize in treating persistent post-surgical pain without additional surgery.

Your treatment plan may include:

• Medical management — optimizing medications for neuropathic and mechanical pain after surgery
• Epidural steroid injections — targeting post-surgical inflammation and scar tissue irritation
• Spinal cord stimulation (SCS) — our most effective tool for failed back surgery, using implantable technology to interrupt pain signals before they reach the brain
• Dorsal root ganglion (DRG) stimulation — targeted neuromodulation for specific nerve pain patterns
• Radiofrequency ablation — for facet-mediated pain above or below the surgical level
• Intrathecal drug delivery — for severe, refractory pain after multiple surgeries
• Medical marijuana certification — for qualifying patients with chronic post-surgical pain

More surgery isn't always the answer. We have advanced, non-surgical treatments that can significantly reduce your pain and improve your quality of life.

Understanding Failed Back Surgery: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind why pain persists after spinal surgery. This research informs how we approach complex post-surgical cases at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed hundreds of patients with persistent or recurrent pain after spinal surgery. These patients represent some of the most complex and challenging cases in pain medicine. They arrive having already undergone the definitive structural intervention — the surgery that was supposed to fix the problem — and yet the pain persists or returns. Many have had multiple surgeries, each with diminishing returns. Most are on chronic opioid therapy. Many have been told that nothing more can be done.

The consistent observation that drives this publication is that failed back surgery is not, in most cases, a failure of surgical technique. The decompression was adequate. The fusion was solid. The hardware is well-positioned. The surgery did what it was designed to do — it corrected the structural lesion. What it could not do was address the biological environment that produced the structural lesion in the first place. The metabolic dysfunction, the systemic inflammation, the hormonal insufficiency, the gut barrier failure, the oxidative stress — the entire biological cascade documented in the companion low back pain publication (Thomas, Alabama Pain Physicians, 2026) — remained active after surgery. Adjacent segment disease, epidural fibrosis, persistent central sensitization, and chronic opioid dependence are the predictable consequences of correcting the structure without correcting the biology.

These publications are my attempt to provide information about this understanding. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background

Failed back surgery syndrome (FBSS) affects an estimated 10–40% of patients who undergo lumbar spinal surgery, with over 80,000 failed back surgeries occurring annually in the United States (PMC, 2018; PubMed, 2023). Repeat surgery shows progressively diminishing returns: while more than 50% of primary surgeries are successful, no more than 30% of second surgeries, 15% of third surgeries, and 5% of fourth surgeries produce successful outcomes (Asian Spine Journal, 2018). Adjacent segment disease develops at a rate of approximately 3.9% per year after fusion, with a 10-year prevalence of 22–36% (PMC, 2010). Higher preoperative body mass index is a significant independent risk factor for adjacent segment disease in a meta-analysis of 7,374 patients (ScienceDirect, 2021). Current management includes revision surgery (success rate 22–40%), spinal cord stimulation, and chronic opioid therapy — each addressing the symptom without modifying the biological environment that produced the initial pathology and continues to drive post-surgical degeneration.

Methods

We conducted a narrative review of PubMed-indexed literature examining failed back surgery syndrome through cellular systems theory, which proposes that post-surgical spinal pain persists because the metabolic, inflammatory, hormonal, microbiome, mitochondrial, and vascular domains that produced the original structural pathology remain active after surgical correction. We reviewed evidence for multi-domain dysfunction in FBSS, analyzed treatment response data for revision surgery and spinal cord stimulation, and constructed composite clinical scenarios illustrating individualized multi-domain assessment.

Results

Published evidence demonstrates that FBSS involves ongoing dysfunction across multiple biological domains beyond the corrected structural lesion: higher BMI is independently associated with adjacent segment disease after fusion; insulin resistance drives continued disc degeneration through AGE accumulation and NF-κB-mediated MMP activation at unfused levels; epidural fibrosis — a fibrotic domain process — is a prevalent cause of chronic post-surgical pain; central sensitization persists after structural correction through glial cell activation independent of the original structural stimulus; and chronic opioid therapy produces HPA axis suppression, testosterone reduction, sleep disruption, weight gain, and gut dysfunction that actively worsen every biological domain driving spinal degeneration.

Conclusions

The pattern of progressively diminishing surgical returns combined with ongoing multi-domain biological dysfunction supports the hypothesis that failed back surgery represents a multi-system cellular disorder in which the structural correction was necessary but insufficient. Cellular systems theory provides a framework for identifying and addressing the biological domains that produced the original pathology and continue to drive post-surgical pain.

1. Introduction

Failed back surgery syndrome is defined by the International Association for the Study of Pain as lumbar spinal pain of unknown origin either persisting despite surgical intervention or appearing after surgical intervention for spinal pain originally in the same topographical location (StatPearls, 2023). The term encompasses a heterogeneous group of patients whose surgical outcomes did not meet pre-surgical expectations, ranging from those with identifiable technical complications to those with anatomically successful surgery and persistent pain. FBSS affects an estimated 10–40% of patients who undergo lumbar spinal surgery, with the estimated incidence potentially exceeding 20% when accounting for patients who do not seek reoperation (PMC, 2017). Over 80,000 failed back surgeries occur annually in the United States (PubMed, 2023). FBSS patients experience higher levels of pain and poorer quality of life than patients with osteoarthritis, rheumatoid arthritis, complex regional pain syndrome, or fibromyalgia (Asian Spine Journal, 2018).

The most striking feature of FBSS is the law of diminishing surgical returns. While more than 50% of primary spinal surgeries produce successful outcomes, no more than 30% of second surgeries, 15% of third surgeries, and 5% of fourth surgeries achieve success (Asian Spine Journal, 2018). This progressive decline is not explained by surgical technique alone. If each surgery correctly addresses its structural target — decompresses the stenosis, removes the recurrent herniation, extends the fusion — why does the success rate fall so dramatically? Cellular systems theory provides an answer: each surgery addresses a structural consequence of biological dysfunction without modifying the biological dysfunction itself. With each passing year, the metabolic, inflammatory, and hormonal environment continues to degrade. Each surgery adds scar tissue, alters biomechanics, and — through the post-operative period of immobilization, opioid use, and deconditioning — actively worsens the metabolic cascade. The fifth surgery attempts to correct structural damage in a body whose biology has deteriorated further since the first.

This publication examines FBSS through the lens of cellular systems theory, building on the metabolic-inflammatory-structural cascade framework established in the companion low back pain publication (Thomas, Alabama Pain Physicians, 2026). The thesis is not that surgery was wrong or unnecessary. In many cases, the structural intervention was appropriately indicated and technically successful. The thesis is that structural correction alone is insufficient when the biological environment that produced the structural damage remains active — and that the post-surgical management paradigm of opioids, inactivity, and repeated interventions systematically worsens the very domains that need to be corrected.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining failed back surgery syndrome through cellular systems theory. Search terms included failed back surgery syndrome, post-laminectomy syndrome, persistent spinal pain syndrome, adjacent segment disease, adjacent segment degeneration, epidural fibrosis combined with metabolic syndrome, insulin resistance, BMI, NF-κB, central sensitization, opioid-induced hyperalgesia, HPA axis, testosterone, microbiome, oxidative stress, and spinal cord stimulation outcomes. We included systematic reviews, meta-analyses, randomized controlled trials, registry studies, and large cohort studies. We analyzed treatment response data from studies of revision surgery, spinal cord stimulation, and opioid therapy. We constructed composite clinical scenarios to illustrate individualized multi-domain assessment.

3. Why Structurally Successful Surgery Fails Clinically

3.1 Adjacent Segment Disease: The Predictable Consequence

Adjacent segment disease — the development of symptomatic degeneration at spinal levels above or below a fusion — is the most compelling evidence that spinal surgery corrects structure without correcting biology. The 10-year prevalence of adjacent segment disease requiring surgery ranges from 22% to 36%, developing at a rate of approximately 3.9% per year after the index fusion (Ghiselli et al., Spine, 2004; Lee et al., European Spine Journal, 2009). Cumulative survival without adjacent segment disease is approximately 93.7% at 5 years but falls to 76.4% at 10 years (Journal of Clinical Medicine, 2025). A meta-analysis of 7,374 patients across 35 studies identified higher preoperative BMI as a significant independent risk factor for adjacent segment disease, with a mean difference of 1.97 kg/m² between patients who developed ASD and those who did not (ScienceDirect, 2021). This finding directly connects the metabolic domain to post-surgical failure.

The conventional biomechanical explanation — that fusion increases mechanical stress on adjacent segments — is incomplete. If altered biomechanics alone drove adjacent segment disease, the rate would be relatively uniform across patients with similar fusion constructs. Instead, higher BMI, preexisting disc degeneration, and vitamin D receptor polymorphisms are risk factors, pointing to biological susceptibility rather than purely mechanical stress. As described in the companion low back pain publication (Thomas, 2026), insulin resistance drives AGE accumulation in disc collagen, NF-κB-mediated MMP activation (Niederberger and Geisslinger, FASEB Journal, 2008), endothelial dysfunction compromising vertebral endplate perfusion, and adipokine-mediated inflammation — the same metabolic cascade that destroyed the first disc. The fusion altered the biomechanics. The biology destroyed the next disc.

3.2 Epidural Fibrosis: The Fibrotic Domain

Epidural fibrosis — scar tissue formation in the epidural space after surgery — is a prevalent cause of chronic post-surgical pain. The surgical exposure itself triggers a wound healing response that, in patients with dysfunctional repair biology, produces excessive scar tissue that adheres to the dura mater and nerve roots. Removal of established epidural fibrosis is technically challenging, increases the risk of dural tears during revision surgery, and frequently recurs because the biological environment promoting fibrosis has not changed (Journal of Yeungnam Medical Science, 2024). Epidural fibrosis represents a structural domain problem — impaired repair leading to fibrosis rather than normal tissue remodeling — driven by upstream inflammatory, hormonal, and metabolic dysfunction. The same inflammatory cytokines that degrade disc collagen promote excessive fibroblast proliferation in the epidural space.

3.3 Persistent Central Sensitization

Central sensitization — a state of neural hyperexcitability in the spinal cord that amplifies pain signals and lowers pain thresholds — can persist after surgical correction of the peripheral pain generator (Woolf, Pain, 2011). Glial cells in the spinal cord dorsal horn, once activated by chronic nociceptive input from the degenerating disc or compressed nerve root, can maintain a sensitized state independent of the original structural stimulus (Watkins and Maier, Physiological Reviews, 2002). This explains why patients with anatomically successful surgery — adequate decompression, solid fusion, well-positioned hardware — continue to experience pain: the structural problem was corrected, but the spinal cord remains primed. Systemic inflammation from any source — metabolic, gut-derived, or adipose-driven — feeds this central sensitization, maintaining the pain state even when the peripheral structural lesion has been resolved.

3.4 The Post-Surgical Opioid Spiral

Chronic opioid therapy after spinal surgery creates a cascade of domain destabilization that systematically worsens every biological system relevant to spinal health. Opioids suppress the HPA axis, reducing cortisol responses and promoting inflammatory disinhibition (Heim et al., Psychoneuroendocrinology, 2000). Opioids reduce testosterone in both men and women, removing anabolic support for tissue repair. Opioids disrupt sleep architecture, reducing the deep sleep stages during which growth hormone release and tissue repair occur (Choy, Nature Reviews Rheumatology, 2015). Opioids cause weight gain, worsening insulin resistance and accelerating the metabolic cascade driving disc degeneration. Opioids cause constipation, altering gut microbiome composition and potentially worsening gut barrier function (Camilleri, Gut, 2019). Opioid-induced hyperalgesia — paradoxically increased pain sensitivity from chronic opioid exposure — can create a state in which the patient’s pain worsens with continued opioid use, necessitating dose escalation that further accelerates every domain destabilization. Up to 24% of patients on chronic opioids for back pain exhibit aberrant medication-taking behaviors (Martell et al., Annals of Internal Medicine, 2007). The post-surgical patient on chronic opioids is often in a worse metabolic, hormonal, inflammatory, and functional state than they were before surgery — not because of the surgery, but because of the post-surgical management paradigm.

3.5 The Law of Diminishing Returns Explained

The progressive decline in surgical success rates — 50% for the first surgery, 30% for the second, 15% for the third, 5% for the fourth — is the predictable consequence of attempting structural correction in a progressively deteriorating biological environment. Each post-surgical period adds more scar tissue, more opioid exposure, more deconditioning, more metabolic deterioration, and more central sensitization. By the time a patient faces a fourth surgery, the biology is profoundly dysfunctional: insulin resistance is advanced, inflammatory markers are chronically elevated, hormones are depleted, gut function is compromised by years of opioid-induced constipation, and the spinal cord is deeply sensitized. A structurally perfect surgical correction in this biological environment has a 5% chance of success — not because the surgery is poorly done, but because the biology cannot support recovery.

4. Evidence for Multi-Domain Dysfunction in Post-Surgical Spinal Pain

The biological domains driving post-surgical spinal pain are the same domains documented in the companion low back pain publication (Thomas, 2026). The critical difference is that post-surgical patients have additional domain insults from the surgery itself, the post-operative opioid exposure, the deconditioning, and the psychological burden of surgical failure. The following sections summarize the evidence specific to the FBSS population.

4.1 Metabolic Domain: BMI and Adjacent Segment Disease

Higher preoperative BMI is independently associated with adjacent segment disease after lumbar fusion, with a significant mean difference confirmed in a meta-analysis of 35 studies encompassing 7,374 patients (ScienceDirect, 2021). This finding is critical because it demonstrates that the metabolic state of the patient at the time of surgery influences long-term structural outcomes at levels the surgery did not touch. Insulin resistance, which correlates with BMI, drives the metabolic cascade of AGE accumulation, NF-κB activation, and endothelial dysfunction that degrades discs systemically (Que et al., Frontiers in Medicine, 2025; Teraguchi et al., PLoS One, 2016). The companion low back pain publication details this cascade extensively. For the FBSS patient, the implication is clear: metabolic optimization before and after surgery could modify the primary risk factor for adjacent segment disease.

4.2 Inflammatory Domain: Persistent Systemic Inflammation

FBSS patients frequently demonstrate elevated inflammatory markers that are not explained by the post-surgical structural findings. This persistent inflammatory tone reflects systemic NF-κB activation from insulin resistance, adipose-derived cytokine production, gut barrier dysfunction, and opioid-induced inflammatory changes. The same inflammatory environment that sensitized the original nerve root continues to sensitize the spinal cord and the nerve roots at unfused levels. Anti-inflammatory interventions targeting a single pathway — whether an NSAID, a corticosteroid injection, or even a revision decompression — cannot suppress inflammation that is being continuously generated by multiple upstream sources.

4.3 Neuroendocrine Domain: Opioid-Induced Hormonal Devastation

Chronic opioid therapy produces measurable endocrine dysfunction including testosterone deficiency (in up to 75% of men on chronic opioids), cortisol suppression, growth hormone reduction, and thyroid axis alteration. These hormonal changes remove the anabolic and anti-inflammatory capacity needed for tissue repair and pain modulation. Sleep disruption from both pain and opioid-altered sleep architecture further reduces growth hormone release (Finan et al., Journal of Pain, 2013). The FBSS patient on chronic opioids is hormonally depleted in every axis relevant to spinal health — testosterone for connective tissue maintenance, cortisol for inflammatory regulation, growth hormone for tissue repair, and thyroid for metabolic rate.

4.4 Microbiome Domain: Opioid-Induced Gut Dysfunction

Opioid-induced constipation affects 40–80% of patients on chronic opioid therapy. Beyond the symptom of constipation, chronic opioids alter gut microbiome composition, reduce intestinal motility, and may increase intestinal permeability (Camilleri, 2019). This gut dysfunction feeds systemic inflammation through LPS translocation and NF-κB activation — the same gut-immune cascade documented in the companion publications. The FBSS patient on chronic opioids has an iatrogenic microbiome domain insult compounding whatever gut dysfunction existed before surgery.

4.5 Structural Domain: Fibrosis and Deconditioning

Epidural fibrosis, adjacent segment degeneration, pseudoarthrosis, and hardware-related complications represent the structural consequences of failed biological recovery. Deconditioning from post-surgical inactivity and pain avoidance produces muscle atrophy, particularly in the multifidus and other paraspinal stabilizers, transferring mechanical load from active muscular support to passive spinal structures. Skeletal muscle loss worsens insulin resistance by reducing the primary tissue for glucose disposal. The deconditioning-metabolic cascade — described extensively in the companion low back pain publication — is accelerated in post-surgical patients by the additional barriers of surgical pain, movement fear, and opioid-induced sedation.

5. Inter-Domain Cascade Mechanics in FBSS

5.1 The Post-Surgical Metabolic Deterioration Cascade

Surgery produces an initial catabolic stress response. Post-operative immobilization and pain-limited activity cause deconditioning and muscle atrophy. Opioid prescriptions cause weight gain, hormonal suppression, and gut dysfunction. Reduced physical activity worsens insulin resistance and eliminates the anti-inflammatory effects of exercise, including endogenous MOTS-c production (Lee et al., Cell Metabolism, 2015). The metabolic environment deteriorates through the post-operative period, reaching a nadir at precisely the time the adjacent discs and unfused segments need the most biological support to withstand altered biomechanics. Adjacent segment disease developing 3–5 years post-fusion reflects the cumulative metabolic deterioration of the post-surgical period, not merely the altered biomechanics of the fusion construct.

5.2 The Opioid-Inflammation-Sensitization Cascade

Chronic opioid exposure produces paradoxical pro-inflammatory effects through Toll-like receptor 4 activation on glial cells, potentially promoting the very central sensitization that opioids are prescribed to treat. Opioid-induced hyperalgesia creates a state in which pain increases despite escalating doses. HPA axis suppression from opioids removes the cortisol-mediated brake on NF-κB activation, allowing systemic inflammation to proceed unchecked. Gut barrier disruption from opioid-induced constipation feeds additional systemic inflammation through LPS translocation. The result is a self-amplifying cycle: opioids suppress pain perception acutely while promoting the inflammatory, hormonal, and metabolic conditions that generate more pain chronically. Dose escalation worsens every domain, necessitating further dose escalation.

5.3 The Fibrosis-Inflammation-Repair Failure Cascade

Surgical trauma triggers an inflammatory wound healing response. In patients with normal biology, this response resolves, producing minimal scar tissue. In patients with dysfunctional repair biology — elevated NF-κB, hormonal insufficiency, oxidative stress, impaired growth hormone release — the wound healing response is dysregulated, producing excessive epidural fibrosis. The fibrotic tissue adheres to the dura and nerve roots, generating new pain that is distinct from the original structural pathology. Revision surgery to address the fibrosis creates more surgical trauma in the same dysfunctional biological environment, producing more fibrosis — a cycle that explains why each subsequent surgery is less likely to succeed and more likely to produce additional scar tissue.

6. Clinical Scenarios: Individualized Domain Assessment

The following composite clinical scenarios illustrate how cellular systems theory guides individualized assessment and intervention for FBSS patients. All laboratory values represent plausible clinical findings consistent with the domain dysfunction documented in the cited studies.

6.1 Patient A: Metabolic-Inflammatory Adjacent Segment Disease

Presentation: 57-year-old man, BMI 38, with L4-5 posterior lumbar interbody fusion performed 4 years ago for degenerative spondylolisthesis. Initial surgery provided 18 months of significant improvement followed by gradual return of low back and bilateral leg pain. MRI shows new moderate stenosis at L3-4 with disc protrusion and facet hypertrophy (adjacent segment disease). Hardware intact, fusion solid. Currently on oxycodone 30 mg daily, gabapentin 1800 mg daily, and duloxetine 60 mg daily. Sleep 4 hours per night. Unable to walk more than 10 minutes. Pain 8/10. Surgeon recommends extension of fusion to L3.

Domain Assessment — Laboratory Findings: Fasting insulin 32 µIU/mL (markedly elevated), HbA1c 6.5% (diabetic threshold), HOMA-IR 8.1 (markedly elevated), triglycerides 286 mg/dL, HDL 30 mg/dL. hs-CRP 7.2 mg/L (significantly elevated). Total testosterone 158 ng/dL (severely low; reference 300–900). Free testosterone critically low. Morning cortisol 3.4 µg/dL (suppressed). DHEA-S markedly low. TSH 4.8 mIU/L with low free T3. Vitamin D 14 ng/mL (deficient). Omega-3 index 1.9% (critically low). RBC magnesium low.

Domain Interpretation: This patient demonstrates the post-surgical metabolic deterioration cascade. Severe insulin resistance — which was likely present but undiagnosed at the time of the index surgery — is driving AGE accumulation, NF-κB activation, and endothelial dysfunction that has destroyed the L3-4 disc just as it destroyed L4-5. Higher BMI is the primary identified risk factor for adjacent segment disease in the meta-analytic literature. Chronic opioid exposure has devastated the neuroendocrine domain: severely low testosterone, suppressed cortisol, and probable growth hormone insufficiency. These hormonal deficiencies remove every anabolic and anti-inflammatory capacity needed for tissue maintenance and repair. Extending the fusion to L3 without addressing this biology will produce the same outcome at L2-3 within 3–5 years. The L3-4 disc is not failing because the L4-5 fusion altered the biomechanics. It is failing because the metabolic environment that destroyed L4-5 has continued, unopposed, to destroy every disc in the spine.

Individualized Protocol: Metabolic optimization as the primary intervention: anti-inflammatory dietary protocol targeting insulin sensitization, guided by continuous glucose monitoring. Opioid taper through structured protocol with interventional procedures (L3-4 epidural, medial branch blocks) for acute pain management during taper. Consider Renew Clinic (TheRenewClinic.com) for Suboxone bridge if opioid taper is not tolerated. Testosterone replacement guided by endocrine assessment. Thyroid optimization. Vitamin D repletion to 50–80 ng/mL. Omega-3 repletion. Magnesium repletion. Graded aquatic exercise program. MOTS-c (5–10 mg SC three times weekly) for AMPK activation and insulin sensitization (Lee et al., Cell Metabolism, 2015). BPC-157 (250–500 µg orally twice daily) for gut barrier restoration during opioid taper and NO restoration (Gwyer et al., Cell and Tissue Research, 2019). GHK-Cu (1–2 mg SC daily) for collagen and GAG stimulation (Pickart and Margolina, 2014; Pickart et al., 2018). Ipamorelin/CJC-1295 at bedtime for growth hormone restoration. DSIP (100–200 µg SC at bedtime) for deep sleep restoration. Defer revision surgery pending 6-month metabolic optimization and reassessment.

6.2 Patient B: Post-Surgical Central Sensitization with Fibrosis

Presentation: 42-year-old woman, BMI 25, with two prior lumbar surgeries: L5-S1 microdiscectomy 5 years ago and L5-S1 revision with fusion 3 years ago. Persistent bilateral leg pain and low back pain despite anatomically adequate decompression and solid fusion on imaging. Pain is burning, widespread in both legs, with allodynia over the lumbar paraspinals and bilateral buttocks. MRI shows epidural fibrosis at L5-S1 but no recurrent stenosis or herniation. Reports anxiety (7/10), poor sleep, food sensitivities, and bloating. Pain 7/10. Currently on gabapentin 2400 mg daily and tramadol as needed. Considering spinal cord stimulator trial.

Domain Assessment — Laboratory Findings: Fasting insulin 10 µIU/mL (normal). HbA1c 5.3% (normal). hs-CRP 3.4 mg/L (mildly elevated). Elevated evening cortisol (HPA axis overactivation). Positive SIBO breath test. Elevated zonulin. Microbiome analysis showing reduced diversity. Vitamin D 25 ng/mL (suboptimal). B12 normal. Hormonal panel otherwise unremarkable.

Domain Interpretation: This patient demonstrates the fibrosis-inflammation-sensitization cascade. Normal metabolic markers exclude insulin resistance as the primary driver. The burning bilateral leg pain with allodynia in the absence of recurrent compression confirms central sensitization (Woolf, 2011). The epidural fibrosis represents dysregulated wound healing from the original surgical trauma in an inflammatory environment. SIBO and elevated zonulin confirm gut barrier dysfunction feeding systemic inflammation through LPS translocation (Camilleri, 2019), which maintains glial cell activation and central sensitization. Elevated evening cortisol reflects HPA axis overactivation from chronic pain stress. Gabapentin addresses one calcium-channel pathway without addressing the gut-immune cascade sustaining the sensitized state. A spinal cord stimulator would modulate the pain signal without modifying the inflammatory biology maintaining the sensitization or the fibrotic tissue generating ongoing nociceptive input.

Individualized Protocol: SIBO treatment per established protocols. Oral BPC-157 (250–500 µg twice daily) for gut barrier restoration (Gwyer et al., 2019). KPV (200–400 µg orally twice daily) for NF-κB inhibition at the gut mucosal level. TB-500 (750 µg to 1.5 mg SC twice weekly) for anti-fibrotic tissue remodeling targeting the epidural fibrosis (Malinda et al., Journal of Investigative Dermatology, 1999). Selank (250–500 µg SC two to three times daily) for anxiety and HPA axis modulation (Zozulia et al., 2008). Elimination dietary protocol. Vitamin D optimization. Graded exposure physical therapy for central sensitization. DSIP (100–200 µg SC at bedtime) for sleep restoration. Reassessment of gut integrity markers, inflammatory markers, cortisol curve, and pain characteristics at 12 weeks. Consider spinal cord stimulator trial after biological optimization if pain persists, recognizing that SCS addresses the pain signal and domain-targeted treatment addresses the biology — both may be needed.

6.3 Patient C: Opioid-Dependent Post-Surgical Metabolic Collapse

Presentation: 63-year-old man with three prior lumbar surgeries over 12 years (microdiscectomy, fusion, revision fusion with extension). Currently on morphine ER 60 mg twice daily plus oxycodone 10 mg for breakthrough. BMI 36 (weight gain of 40 pounds since first surgery). Reports fatigue, depression, low libido, constipation requiring daily laxatives, and poor sleep. MRI shows multilevel degenerative changes but no acute surgical target. Surgeon has indicated no further surgical options. Referred for “pain management.” Pain 7/10 constantly.

Domain Assessment — Laboratory Findings: Fasting insulin 28 µIU/mL (elevated), HbA1c 6.6% (diabetic). hs-CRP 8.8 mg/L (markedly elevated). Total testosterone 112 ng/dL (critically low). Morning cortisol 2.8 µg/dL (profoundly suppressed). DHEA-S undetectable. TSH 5.6 mIU/L with low free T3 and T4. Vitamin D 12 ng/mL (severely deficient). Omega-3 index 1.4% (critically low). Organic acids showing marked mitochondrial dysfunction markers and elevated 8-OHdG (oxidative DNA damage). Microbiome analysis showing severely reduced diversity.

Domain Interpretation: This patient demonstrates the full opioid-induced metabolic collapse. Twelve years of chronic opioid therapy has produced endocrine devastation (critically low testosterone, profoundly suppressed cortisol, hypothyroid pattern, undetectable DHEA-S), metabolic syndrome progression to diabetes, marked systemic inflammation, severe oxidative stress with mitochondrial dysfunction, and gut microbiome destruction. His biology is in worse condition than it was before his first surgery. The opioids that were prescribed to manage post-surgical pain have produced a metabolic and hormonal environment in which no tissue can repair, no inflammation can resolve, and every remaining disc and joint structure is under sustained biological assault. There is no surgical target because the problem is not structural — it is biological. He has not been told nothing can be done. He has been told that the wrong things have been tried for twelve years.

Individualized Protocol: Opioid transition through Renew Clinic (TheRenewClinic.com) Suboxone protocol with close monitoring. Comprehensive metabolic optimization: anti-inflammatory dietary protocol, guided insulin sensitization, graded movement program beginning with aquatic therapy. Testosterone replacement. Thyroid optimization. Cortisol assessment and adrenal support guided by endocrine evaluation. Vitamin D repletion. Omega-3 repletion. MOTS-c (5–10 mg SC three times weekly) for metabolic optimization (Lee et al., 2015). BPC-157 (250–500 µg orally twice daily) for gut barrier restoration during opioid transition (Gwyer et al., 2019). NAD+ (IV 250–500 mg 1–2x weekly for loading) for mitochondrial energy substrate. Glutathione (IV 600–1200 mg 1–2x weekly) for antioxidant defense. SS-31 (5–10 mg SC daily) for mitochondrial membrane stabilization (Szeto, 2014; Birk et al., 2013). Ipamorelin/CJC-1295 at bedtime for growth hormone restoration. DSIP (100–200 µg SC at bedtime) for sleep architecture restoration. Serial reassessment of metabolic, hormonal, inflammatory, and mitochondrial markers at 12-week intervals. This patient requires 12–24 months of sustained biological optimization.

7. Emerging Peptide Therapeutics: Domain-Targeted Intervention

Peptide therapeutics offer potential for domain-targeted intervention in FBSS. The following peptides have published evidence connecting their mechanisms to biological domains documented as dysfunctional in post-surgical spinal pain. Evidence is extrapolated from mechanism-of-action studies and trials in related conditions.

TB-500 promotes cell migration to injured tissue and anti-fibrotic tissue remodeling, promoting proper tissue remodeling rather than scar formation (Malinda et al., Journal of Investigative Dermatology, 1999). Its anti-fibrotic property makes it uniquely relevant to epidural fibrosis, the fibrotic domain pathology that is a prevalent cause of chronic post-surgical pain. Subcutaneously at 750 µg to 1.5 mg twice weekly. Not FDA-approved.

BPC-157 has demonstrated nerve regeneration in preclinical models of sciatic nerve transection (Gjurasin et al., Regulatory Peptides, 2010) and spinal cord injury (Perovic et al., Journal of Orthopaedic Surgery and Research, 2019), restores gut barrier integrity, and restores nitric oxide production in blood vessel walls (Gwyer et al., Cell and Tissue Research, 2019). Its combined nerve regeneration, gut barrier repair, and endothelial function restoration address three domain insults common in FBSS patients. Orally at 250–500 µg twice daily or subcutaneously. Not FDA-approved.

MOTS-c activates AMPK to improve insulin sensitivity and reduce inflammatory cytokines (Lee et al., Cell Metabolism, 2015). Targets the insulin resistance documented as a risk factor for adjacent segment disease and the metabolic cascade driving continued spinal degeneration. Subcutaneously at 5–10 mg three times weekly. Not FDA-approved.

GHK-Cu stimulates collagen, elastin, and glycosaminoglycan production and modulates approximately 32% of human gene expression toward repair patterns (Pickart and Margolina, 2014; Pickart et al., 2018). Directly targets disc matrix components at unfused levels. Subcutaneously at 1–2 mg daily. Not FDA-approved.

SS-31 (elamipretide) stabilizes the inner mitochondrial membrane by binding cardiolipin (Szeto, 2014; Birk et al., 2013; Karaa et al., 2018). Addresses the mitochondrial dysfunction documented in patients with chronic pain, opioid exposure, and metabolic syndrome. Subcutaneously at 5–10 mg daily. Not FDA-approved for pain.

DSIP promotes delta-wave deep sleep architecture for growth hormone release and tissue repair (Choy, 2015; Finan et al., 2013). Critically relevant for FBSS patients whose sleep architecture has been disrupted by both chronic pain and opioid exposure. Subcutaneously at 100–200 µg at bedtime. Not FDA-approved.

Selank modulates GABA for anxiolysis without sedation (Zozulia et al., 2008). Addresses the anxiety and HPA axis dysfunction common in FBSS patients without the cognitive or metabolic side effects of benzodiazepines or antidepressants. Subcutaneously at 250–500 µg two to three times daily. Not FDA-approved in the US.

Peptide protocols are individualized based on domain assessment findings. Additional peptides targeting hormonal restoration, immune regulation, and detoxification may be indicated based on individual assessment.

8. Discussion

The evidence reviewed in this paper supports three propositions. First, failed back surgery syndrome involves measurable, ongoing dysfunction across multiple biological domains that persists after structural surgical correction. Adjacent segment disease is driven by metabolic factors (higher BMI as independent risk factor). Epidural fibrosis reflects dysregulated wound healing in an inflammatory environment. Central sensitization persists through glial cell activation independent of the original structural stimulus. Chronic opioid therapy produces endocrine devastation, metabolic deterioration, gut dysfunction, and paradoxical pro-inflammatory effects.

Second, the law of diminishing surgical returns — from 50% success at the first surgery to 5% at the fourth — is the predicted outcome of attempting repeated structural correction in a progressively deteriorating biological environment. Each post-surgical period adds metabolic, hormonal, inflammatory, and fibrotic insults that make the next structural repair less likely to succeed. The declining success rate is not evidence that surgery is futile. It is evidence that surgery alone is insufficient.

Third, the post-surgical management paradigm of chronic opioid therapy systematically worsens every biological domain relevant to spinal health. Opioids suppress hormones needed for repair, disrupt sleep needed for recovery, cause weight gain that worsens metabolic disease, impair gut function, and may paradoxically increase pain sensitivity. The post-surgical opioid spiral is not an inevitable consequence of surgery. It is a treatable cascade that cellular systems analysis can identify and address.

This publication does not argue against spinal surgery. Surgery is essential for acute structural emergencies and appropriately indicated degenerative conditions. It argues that surgical outcomes can be improved — and adjacent segment disease potentially reduced — by addressing the metabolic, inflammatory, hormonal, and microbiome domains before, during, and after the surgical intervention. For patients who already have FBSS, cellular systems analysis offers an approach beyond the choice between revision surgery, spinal cord stimulation, and chronic opioid therapy.

Limitations include the narrative methodology, the absence of prospective trials testing metabolic optimization as an adjunct to spinal surgery, the preclinical basis of most peptide evidence, and the inherent complexity of the FBSS population. Prospective trials comparing domain-targeted metabolic optimization combined with standard surgical and interventional care versus standard care alone are needed.

9. Conclusion

Failed back surgery syndrome is treated as a structural problem requiring structural solutions — revision surgery, spinal cord stimulation, or acceptance of chronic pain with opioid management. Yet the published evidence demonstrates that the biological environment driving spinal degeneration persists after surgery, that adjacent segment disease is predicted by metabolic factors, that epidural fibrosis reflects dysfunctional repair biology, and that chronic opioid therapy systematically worsens every domain relevant to spinal health. The law of diminishing surgical returns is the clearest evidence that structural correction without biological correction is insufficient. Cellular systems theory provides a framework for understanding why the surgery succeeded structurally but failed clinically, and for directing treatment toward the metabolic, inflammatory, hormonal, and microbiome domains that produced the original pathology and continue to drive post-surgical pain. For the patient told that nothing more can be done, something different can be tried.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management, including interventional procedures and spinal cord stimulation. For opioid recovery services, visit TheRenewClinic.com. Contact: 205.332.3160. BamaPain.com.

Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels, peptide therapeutics, interventional procedures, and spinal cord stimulation described in this review as clinical services. No external funding was received for this work.

References

1. Sebaaly A, Lahoud MJ, Rizkallah M, Kreichati G, Kharrat K. Failed back surgery syndrome: etiology, evaluation, and treatment. Asian Spine Journal. 2018;12(3):574-585.

2. Prevalence, characteristics, and burden of failed back surgery syndrome. PMC. 2017.

3. Prevalence of FBSS across HCA Healthcare in the United States. PubMed. 2023.

4. Failed back surgery syndrome: terminology, etiology, prevention, evaluation, and management. Journal of Yeungnam Medical Science. 2024.

5. Failed back surgery syndrome. StatPearls. 2023.

6. Risk factors analysis and risk prediction model for FBSS. ScienceDirect. 2024.

7. Ghiselli G, Wang JC, Bhatia NN, Hsu WK, Dawson EG. Adjacent segment degeneration in the lumbar spine. J Bone Joint Surg Am. 2004;86(7):1497-1503.

8. Lee CS, Hwang CJ, Lee SW, et al. Risk factors for adjacent segment disease after lumbar fusion. Eur Spine J. 2009;18(11):1637-1643.

9. Temporal patterns of risk factors for adjacent segment disease after lumbar fusion. J Clin Med. 2025;14(10):3400.

10. Demographic, clinical, and operative risk factors associated with postoperative adjacent segment disease: systematic review and meta-analysis. ScienceDirect. 2021.

11. Incidence and risk factors for adjacent segment disease after TLIF. Int J Gen Med. 2021;14:8185-8192.

12. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB Journal. 2008;22(10):3432-3442.

13. Que Z, et al. Insulin resistance and low back pain in US adults. Frontiers in Medicine. 2025;12:1538754.

14. Teraguchi M, et al. Metabolic syndrome and disc degeneration. PLoS One. 2016;11(2):e0147565.

15. Woolf CJ. Central sensitization. Pain. 2011;152(3 Suppl):S2-S15.

16. Watkins LR, Maier SF. Immune and glial cells in pathological pain. Physiological Reviews. 2002;82(4):981-1011.

17. Heim C, et al. Hypocortisolism in stress-related disorders. Psychoneuroendocrinology. 2000;25(1):1-35.

18. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

19. Finan PH, et al. Sleep and pain association. Journal of Pain. 2013;14(12):1539-1552.

20. Choy EH. Sleep in pain and fibromyalgia. Nature Reviews Rheumatology. 2015;11(9):513-520.

21. Martell BA, et al. Opioid treatment for chronic back pain. Annals of Internal Medicine. 2007;146(2):116-127.

22. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015;21(3):443-454.

23. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell and Tissue Research. 2019;377(2):153-159.

24. Gjurasin M, et al. BPC 157 in traumatic nerve injury. Regulatory Peptides. 2010;160(1-3):33-41.

25. Perovic D, et al. BPC 157 in spinal cord injury. J Orthop Surg Res. 2019;14(1):199.

26. Malinda KM, et al. Thymosin beta4 in wound healing. J Invest Dermatol. 1999;113(3):364-368.

27. Pickart L, Margolina A. GHK and DNA: resetting the genome. BioMed Res Int. 2014;2014:151479.

28. Pickart L, et al. GHK-Cu regenerative actions. Int J Mol Sci. 2018;19(7):1987.

29. Szeto HH. Cardiolipin-protective compound. Br J Pharmacol. 2014;171(8):2029-2050.

30. Birk AV, et al. SS-31 re-energizes mitochondria. JASN. 2013;24(8):1250-1261.

31. Karaa A, et al. Elamipretide in mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.

32. Zozulia AA, et al. Selank in generalized anxiety. Zh Nevrol Psikhiatr. 2008;108(4):38-48.

33. Brinjikji W, et al. Imaging features of spinal degeneration in asymptomatic populations. AJNR. 2015;36(4):811-816.

34. Zhai X, et al. Chronic pain and insulin resistance. J Pain. 2016;17:404-413.

35. Risbud MV, Shapiro IM. Cytokines in disc degeneration. Nat Rev Rheumatol. 2014;10(1):44-56.

36. Helde-Frankling M, et al. Vitamin D in pain management. IJMS. 2017;18(10):2170.

© 2026 Alabama Pain Physicians. All rights reserved.